(P050) Hypothyroidism After Definitive Radiation Therapy for Oropharyngeal Cancer

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

We conducted a retrospective cohort study of oropharyngeal cancer patients to evaluate the incidence of hypothyroidism after definitive radiation therapy.

Chiaojung J. Tsai, MD, PhD, Guojun Li, PhD, Erich M. Sturgis, MD, Adam S. Garden, MD; UT MD Anderson Cancer Center

Purpose and Objective: We conducted a retrospective cohort study of oropharyngeal cancer patients to evaluate the incidence of hypothyroidism after definitive radiation therapy (RT).

Materials and Methods: Follow-up records of 439 oropharyngeal cancer patients staged I–IVb and treated with definitive RT between January 2000 and October 2008 were reviewed. The occurrence of hypothyroidism was defined as elevated levels of thyroid-stimulating hormone (TSH) above 5.50 mcU/mL. Patients with baseline hypothyroidism before treatment were excluded from the study. Cox proportional hazards analysis was used to compute hazard ratios (HRs) comparing patients with and without hypothyroidism.

Results: A total of 408 out of 439 patients had follow-up data on TSH levels and were included in the analysis; 200 patients (49%) developed hypothyroidism after radiation. The median time to developing hypothyroidism was 12 months (range: 1–69 mo). Of the 200 patients with hypothyroidism, 13 (7%) did not take oral thyroid hormone replacement, and their median TSH was 5.84 mcU/mL (range: 5.53–8.38 mcU/mL). Further, 156 of the 200 patients had information on thyroid hormone replacement use, and their median TSH level was 7.4 mcU/mL (range: 5.55–119 mcU/mL). There was no difference in the occurrence of hypothyroidism between patients treated with 3D-conformal radiation vs intensity-modulated RT ([IMRT] 54% and 48%, respectively; chi-square P = .34). Patients who received ≥ 70 Gy of the prescribed radiation dose to the primary tumor had a higher risk of hypothyroidism compared with those whose prescription dose was < 70 Gy (55% and 44%, respectively; P = .04). In univariate Cox proportional hazards analyses, patients who were never-smokers had a higher risk of hypothyroidism compared with current smokers (HR = 1.6; P = .02). Age, sex, treatment technique (3D vs IMRT), clinical T category, clinical N category, and chemotherapy use were not significantly associated with hypothyroidism risk. Multivariate Cox proportional models demonstrated elevated risk of hypothyroidism among never-smokers (HR = 1.6; P = .02) and those who received a prescribed radiation dose of 70 Gy or more (HR = 1.2; P = .04) after adjusting for age, sex, treatment technique, and chemotherapy use.

Conclusion: Patients who received a radiation prescription dose of 70 Gy or more to the primary tumor and were never-smokers had an increased risk of hypothyroidism after definitive RT for oropharyngeal cancer.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content